news
GSK and Novartis ‘misled’ consumers, says Federal Court of Australia
GSK and Novartis found to have misled consumers with the packaging and pricing of their osteoarthritis pain treatment.
List view / Grid view
Novartis
article
Formulation In-Depth Focus 2019
As today’s scientists continue to identify new biopharmaceutical products with potential to treat a wide array of diseases, formulation remains the determining factor in their success. But what is involved in these increasingly complex formulation processes and how do they impact the packaging and delivery systems?
news
Europe-Africa partnership spearheads development of next-generation antimalarial drug
The grant will support African trials of a novel antimalarial combination comprising KAF156 (ganaplacide) and lumefantrine in a new once-daily formulation...
news
Top novel drug approvals: February 2019
Cablivi and Egaten were the two top novel drugs approved last month, with a focus on parasitic infestation and the rare disorder, aTTP...
news
Expansion of the global antibiotics market size
The global antibiotics market is set to increase at a CAGR of 4 percent to $62.06 billion, due to the rising prevalence of infectious diseases...
news
Sales of generic oncology drugs surge
A report has forecasted that the generic oncology drugs market could register an impressive 6 percent CAGR up to the year 2028...
news
Late-stage pipeline drugs could compete with only treatment for SMA
A number of drugs currently in their late stages in the development process could see competition for nusinersen, the only current SMA treatment, rise...
news
NHS announces groundbreaking personalised child cancer treatment
The NHS has announced a groundbreaking new treatment, CAR-T, for children with leukaemia...
news
Aimovig approved by EU for migraine prevention
Researchers found that more than one quarter (26 per cent) of patients taking Aimovig 70mg were migraine free after month 15...
news
FDA approves the inclusion of new evidence for Cosentyx in PsA
The FDA has approved the inclusion of new evidence that Cosentyx significantly slows the progression of joint structural damage..
news
FDA expands approval of Gilenya to treat multiple sclerosis in paediatric patients
The FDA has approved Gilenya to treat relapsing multiple sclerosis in children and adolescents age 10 years and older...
news
Novartis invests $100 mn to eliminate malaria
Novartis is to invest more than $ 100 million to advance research and development of new antimalarials over the next five years...
news
Novartis forms alliance to develop medicines for cryptosporidiosis
Novartis and the Bill & Melinda Gates Foundation have formed an alliance to advance the development of Novartis' drug candidate KDU731...
news
FDA approves Glatopa a generic option for relapsing forms of multiple sclerosis
Sandoz has announced that the FDA has approved and launch of Glatopa as a fully-substitutable, AP-rated generic version of Copaxone for relapsing forms of MS...
news
Promacta receives Breakthrough Therapy designation for SAA
The FDA has granted Breakthrough Therapy designation to Promacta for use in combination with standard immunosuppressive therapy for severe aplastic anaemia...
